This is the authors' abstract. We don't add key points for this paper.
Multiple sclerosis (MS) is a complex immune‐mediated disease of the central nervous system. Traditionally, it has been considered to be mediated primarily by T cells, and the contribution of B cells in the pathogenesis of MS has long been debated. However, clinical success of B‐cell depletion therapies targeting CD20 has established the essential role of B cells in the pathogenesis of MS. Because CD20‐targeting B‐cell depletion therapies primarily have their effect on non‐antibody secreting cells, emerging studies have dedicated intense focus on B‐cell functions beyond antibody production, which include cytokine production, antigen presentation and ectopic lymphoid follicle‐like structure formation. However, the failure of atacicept, which targets the B‐cell survival factors and a proliferation‐inducing ligand, suggests that B cells potentially have a dual role in the pathogenesis of MS and the role of B cells in MS is highly complex. This review will discuss the B‐cell involvement in the pathogenesis of MS.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hirofumi Ochi (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: